Cited by 4,148Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Innate and adaptive immune cells in the tumor microenvironment

Open access

Gajewski, Thomas F, Schreiber, Hans, Fu, Yang-Xin·2013·Nature Immunology

Open this paper in CoChat — free account

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2703

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Flagged first, then by citations

Show all 149 references

Research works printed but not linked: 1

Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. (in the press).

Sorted by citations

Items 801–900 of 1,004

CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer
Zhang, S., Zhong, M., Wang, C., Xu, Y., Gao, W., & Zhang, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0796-2 · Cited by 70
Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids
Cai, C., Koch, B., Morikawa, K., Suda, G., Sakamoto, N., Rueschenbaum, S., Akhras, S., Dietz, J., Hildt, E., Zeuzem, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00723 · Cited by 68
Tumor immunotherapy: New aspects of natural killer cells
Li, Y., & Sun, R. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.02 · Cited by 71
Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions
Kreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 68
Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer
Zhang, Y., Yu, M., Jing, Y., Cheng, J., Zhang, C., Cheng, L., Lu, H., Cai, M., Wu, J., Wang, W., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01123-w · Cited by 68
The Emerging Role of Nerves and Glia in Colorectal Cancer
Schonkeren, S. L., Thijssen, M. S., Vaes, N., Boesmans, W., & Melotte, V. (2021) · Cancers · doi:10.3390/cancers13010152 · Cited by 71
Boosting Tumor Immunotherapy by Bioactive Nanoparticles via Ca2+ Interference Mediated TME Reprogramming and Specific PD‐L1 Depletion
An, J., Liu, M., Zhao, L., Lu, W., Wu, S., Zhang, K., Liu, J., Zhang, Z., & Shi, J. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202201275 · Cited by 68
Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
Fang, P., Zhou, J., Liang, Z., Yang, Y., Luan, S., Xiao, X., Li, X., Zhang, H., Shang, Q., Zeng, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975986 · Cited by 68
Hypoxia induced lactate acidosis modulates tumor microenvironment and lipid reprogramming to sustain the cancer cell survival
Singh, L., Nair, L. S., Kumar, D., Arora, M. K., Bajaj, S., Gadewar, M. M., Mishra, S. S., Rath, S. K., Dubey, A. K., Kaithwas, G., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1034205 · Cited by 73
The interplay between the microbiome and the adaptive immune response in cancer development
Russo, E., Taddei, A., Ringressi, M. N., Ricci, F., & Amedei, A. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16635082 · Cited by 68
Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy
Mühlberger, M., Janko, C., Unterweger, H., Friedrich, R. P., Friedrich, B., Band, J., Cebulla, N., Alexiou, C., Dudziak, D., Lee, G., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s218488 · Cited by 71
Angiocrine endothelium: from physiology to cancer
Pasquier, J., Ghiabi, P., Chouchane, L., Razzouk, K., Rafii, S., & Rafii, A. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02244-9 · Cited by 68
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
Plesca, I., Tunger, A., Müller, L., Wehner, R., Lai, X., Grimm, M., Rutella, S., Bachmann, M. P., & Schmitz, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00364 · Cited by 71
Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus
Wan, P. K.-T., Ryan, A. J., & Seymour, L. W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.015 · Cited by 67
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 65
Cell surface–tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy
Jones, D. S., Nardozzi, J. D., Sackton, K. L., Ahmad, G., Christensen, E., Ringgaard, L., Chang, D.-K., Jæhger, D. E., Konakondla, J. V. V., Wiinberg, M., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi8075 · Cited by 65
Harnessing immune response using reactive oxygen Species-Generating/Eliminating inorganic biomaterials for disease treatment
Zhao, C., Deng, H., & Chen, X. S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114456 · Cited by 71
Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy
Luo, K.-W., Li, N., Ye, W., Gao, H., Luo, X., & Cheng, B. (2022) · Molecules · doi:10.3390/molecules27144638 · Cited by 68
Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review
Aghapour, S. A., Torabizadeh, M., Bahreiny, S. S., Saki, N., Far, M. A. J., Avarvand, A. Y., Ghasemi, K. D. M., Aghaei, M., Abolhasani, M. M., Sharifani, M. S., et al. (2024) · Iranian Journal of Blood and Cancer · doi:10.61186/ijbc.16.2.84 · Cited by 71
Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy
Matsumoto, M., Takeda, Y., Tatematsu, M., & Seya, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01897 · Cited by 67
Red fluorescent cAMP indicator with increased affinity and expanded dynamic range
Ohta, Y., Furuta, T., Nagai, T., & Horikawa, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-20251-1 · Cited by 67
Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients
Dimitriou, N., Felekouras, E. S., Karavokyros, I., Alexandrou, A. P., Pikoulis, E., & Grınıatsos, J. (2018) · BMC Cancer · doi:10.1186/s12885-018-5042-x · Cited by 67
Immune‑related adverse events during anticancer immunotherapy: Pathogenesis and management (Review)
Stucci, L. S., Palmirotta, R., Passarelli, A. M., Silvestris, E., Argentiero, A., Lanotte, L., Acquafredda, S., Todisco, A., & Silvestris, F. (2017) · Oncology Letters · doi:10.3892/ol.2017.6919 · Cited by 67
Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients
Falk, A. T., Yazbeck, N., Guibert, N. M., Chamorey, E., Paquet, A. C., Ribeyre, L., Bence, C., Zahaf, K., Leroy, S., Marquette, C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.009 · Cited by 70
Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3–CD8+ T cells
Deng, S., Sun, Z., Qiao, J., Liang, Y., Liu, L., Dong, C., Shen, A., Wang, Y., Tang, H., Fu, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132000 · Cited by 67
Self-citation
Regulation of antitumor immunity by inflammation-induced epigenetic alterations
Karin, M., & Shalapour, S. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00756-y · Cited by 68
cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response
Bose, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112456 · Cited by 69
Cytosolic Delivery of Thiolated Neoantigen Nano‐Vaccine Combined with Immune Checkpoint Blockade to Boost Anti‐Cancer T Cell Immunity
Zhang, D., Lin, Z., Wu, M., Cai, Z., Zheng, Y., He, L., Li, Z., Zhou, J. J., Sun, L., Chen, G., et al. (2021) · Advanced Science · doi:10.1002/advs.202003504 · Cited by 64
Discovery and development of tumor glycolysis rate-limiting enzyme inhibitors
Sun, X., Peng, Y., Zhao, J., Xie, Z., Lei, X., & Tang, G. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104891 · Cited by 70
Therapeutic potential of interleukin‑15 in cancer (Review)
Isvoranu, G., Surcel, M., Munteanu, A. N., Bratu, O. G., Radu, F. I., Neagu, M. T., & Chiritoiu‐Butnaru, M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10107 · Cited by 65
Reduction Sensitive Polymers Delivering Cationic Platinum Drugs as STING Agonists for Enhanced Chemo‐Immunotherapy
Zhang, L., Shang, K., Li, X., Shen, M., Lü, S., Tang, D., Han, H., & Yu, Y. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204589 · Cited by 65
Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment
Guo, Q., Li, J., & Lin, H. (2015) · BioMed Research International · doi:10.1155/2015/261620 · Cited by 65
Long non-coding RNA expression profile in minor salivary gland of primary Sjögren’s syndrome
Shi, H., Cao, N., Pu, Y., Xie, L., Zheng, L., & Yu, C. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1005-2 · Cited by 65
New Insights into Regulatory T Cells: Exosome- and Non-Coding RNA-Mediated Regulation of Homeostasis and Resident Treg Cells
Li, P., Liu, C., Yu, Z., & Wu, M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00574 · Cited by 65
Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype
Borgoni, S., Iannello, A., Cutrupi, S., Allavena, P., D’Incalci, M., Novelli, F., & Cappello, P. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393596 · Cited by 65
Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection
Diao, P., Wu, Y., Li, J., Zhang, W., Huang, R., Zhou, C., Wang, Y., & Cheng, J. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1742-x · Cited by 67
Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma
Hei, Y., Teng, B., Zeng, Z., Zhang, S., Li, Q., Pan, J., Luo, Z., Xiong, C., & Wei, S. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s225807 · Cited by 65
Long noncoding RNA: Novel links between gene expression and innate immunity
Carpenter, S. B. (2015) · Virus Research · doi:10.1016/j.virusres.2015.08.019 · Cited by 63
Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy
Yaman, S., Chintapula, U. K., Rodriguez, E., Ramachandramoorthy, H., & Nguyen, K. T. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.55 · Cited by 64
Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases
Bu, Y., Wu, H., Deng, R., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.733387 · Cited by 66
Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer
Adewunmi, O., Shen, Y., Zhang, X. H.-F., & Rosen, J. M. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0045 · Cited by 73
Role of immune system in tumor progression and carcinogenesis
Upadhyay, S., Sharma, N., Gupta, K. B., & Dhiman, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26663 · Cited by 65
Long noncoding RNA lnc-sox5 modulates CRC tumorigenesis by unbalancing tumor microenvironment
Wu, K., Zhao, Z., Liu, K., Zhang, J., Li, G., & Wang, L. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1317416 · Cited by 63
TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment
Zhu, H., Hu, X., Gu, L., Jian, Z., Li, L., Hu, S., Qiu, S., & Xiong, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.759953 · Cited by 62
Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity
Luan, X., Lei, T., Fang, J., Liu, X., Fu, H., Li, Y., Chu, W., Jiang, P., Tong, C., Qi, H., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.010 · Cited by 63
Self-citation
A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer
Han, P.-Z., Ye, W.-D., Yu, P., Tan, L.-C., Xiao Hua, S. H. I., Chen, X.-F., He, C., Hu, J., Wei, W., Lu, Z., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.173712 · Cited by 69
CD8+CXCR5+ T cells in tumor-draining lymph nodes are highly activated and predict better prognosis in colorectal cancer
Jifu, E., Yan, F., Kang, Z., Zhu, L., Xing, J., & Yu, E. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.03.003 · Cited by 63
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
Kaderbhaï, C., Tharin, Z., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11020201 · Cited by 63
ITCH as a potential therapeutic target in human cancers
Yin, Q., Wyatt, C. J., Han, T., Smalley, K. S. M., & Wan, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.003 · Cited by 60
Prognostic and Immunological Role of mRNA ac4C Regulator NAT10 in Pan-Cancer: New Territory for Cancer Research?
Yang, C.-X., Wu, T., Zhang, J., Liu, J.-H., Zhao, K., Sun, W., Zhou, X., Kong, X., & Shi, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2021.630417 · Cited by 59
Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer
Jaiswal, A., Murakami, K., Elia, A., Shibahara, Y., Done, S. J., Wood, S. A., Donato, N. J., Ohashi, P. S., & Reedijk, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101592118 · Cited by 64
Trial watch: intratumoral immunotherapy
Humeau, J., Naour, J. L., Galluzzi, L., Kroemer, G., & Pol, J. G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1984677 · Cited by 62
Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model
Ruiz-Martínez, Á., Gong, C., Wang, H., Sové, R. J., Mi, H., Kimko, H. H. C., & Popel, A. S. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010254 · Cited by 62
Macrophage phenotype-switching in cancer
Zhang, J., Zhou, X., & Hao, H. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175229 · Cited by 63
Inflammation and prostate cancer: friends or foe?
Taverna, G., Pedretti, E., Caro, G. D., Borroni, E. M., Marchesi, F., & Grizzi, F. (2015) · Inflammation Research · doi:10.1007/s00011-015-0812-2 · Cited by 62
New perspectives on type I IFNs in cancer
Gajewski, T. F., & Corrales, L. P. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.01.001 · Cited by 62
Self-citation
CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-β pathway in human non-small cell lung cancer
Liu, W., Wei, X., Li, L., Wu, X., Yan, J., Yang, H. L., & Song, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.034 · Cited by 62
T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma
Leivonen, S., Pollari, M., Brück, O. E., Pellinen, T. S., Autio, M. I., Karjalainen‐Lindsberg, M., Mannisto, S., Kellokumpu‐Lehtinen, P., Kallioniemi, O., Mustjoki, S. M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.200105 · Cited by 63
Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer
Wang, J. T., Li, H., Zhang, H., Chen, Y., Cao, Y., Li, R., Lin, C., Wei, Y., Xiang, X., Fang, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy505 · Cited by 62
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
Humphries, M. P., Hynes, S. O., Bingham, V., Cougot, D., James, J. A., Patell-Socha, F., Parkes, E. E., Blayney, J. K., O’Rorke, M. A., Irwin, G. W., et al. (2018) · Journal of Oncology · doi:10.1155/2018/2937012 · Cited by 63
Macrophages in Colorectal Cancer Liver Metastases
Cortese, N., Soldani, C., Franceschini, B., Barbagallo, M., Marchesi, F., Torzilli, G., & Donadon, M. (2019) · Cancers · doi:10.3390/cancers11050633 · Cited by 63
Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4+ T Cells
Magen, A., Nie, J., Ciucci, T., Tamoutounour, S., Zhao, Y., Mehta, M., Tran, B. Q., McGavern, D. B., Hannenhalli, S. S., & Bosselut, R. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.131 · Cited by 63
Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Jaeger, A. M., Stopfer, L. E., Lee, S., Gaglia, G., Sandel, D. A., Santagata, S., Lin, N., Trepel, J. B., White, F. M., Jacks, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0596 · Cited by 61
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade
Liu, Y., Cai, J., Liu, W., Lin, Y., Guo, L., Liu, X., Qin, Z., Xu, C., Zhang, Y., Su, X., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03285-0 · Cited by 61
Organoid models of the tumor microenvironment and their applications
Xia, T., Du, W., Chen, X., & Zhang, Y.-N. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16578 · Cited by 63
Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
Jørgensen, M. A., Ugel, S., Hübbe, M. L., Carretta, M., Perez-Penco, M., Weis-Banke, S. E., Martinenaite, E., Kopp, K., Chapellier, M., Adamo, A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0280 · Cited by 63
A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology
Hu, B., Sajid, M., Lv, R., Liu, L., & Sun, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996721 · Cited by 60
IGSF8 is an innate immune checkpoint and cancer immunotherapy target
Li, Y., Wu, X., Sheng, C., Liu, H., Liu, H., Tang, Y., Liu, C., Ding, Q., Xie, B., Xiao, X., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.039 · Cited by 66
Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?
Taghizadeh-Anvar, M., Rashidan, K., Arsam, N., Rasouli‐Saravani, A., Yadegari, H., Ahmadi, A., Asgari, Z., Vanan, A. G., Ghorbaninezhad, F., & Tahmasebi, S. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03525-9 · Cited by 67
Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion
Yang, X., Huang, C., Zhong, M., Zhong, H., Ruan, R., Xiong, J., Yao, Y., Zhou, J., & Deng, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02033-1 · Cited by 70
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.
Santarpía, M., González‐Cao, M., Viteri, S., Karachaliou, N., Altavilla, G., & Rosell, R. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.12.04 · Cited by 61
Biomarkers for Immune Checkpoint Inhibitors in Melanoma
Kitano, S., Nakayama, T., & Yamashita, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00270 · Cited by 63
Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features
Mojarad, E. N., Mohammadpour, S., Esfahani, A. T., Gharib, E., Larki, P., Moradi, A., Pourhoseingholi, M. A., Aghdaei, H. A., Kuppen, P. J. K., & Zali, M. R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27273 · Cited by 60
Warburg Effect Is a Cancer Immune Evasion Mechanism Against Macrophage Immunosurveillance
Chen, J., Cao, X., Li, B., Zhao, Z., Chen, S., Lai, S. W. T., Muend, S., Nossa, G., Wang, L., Guo, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621757 · Cited by 59
Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation
Crump, N. T., Hadjinicolaou, A. V., Meng, X., Walsby-Tickle, J., Gileadi, U., Chen, J., Setshedi, M., Olsen, L. R., Lau, I., Godfrey, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109101 · Cited by 61
Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
Xu, Y., Chen, C., Guo, Y., Hu, S., & Sun, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848327 · Cited by 66
Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression
Fassler, D., Torre-Healy, L. A., Gupta, R., Hamilton, A. M., Kobayashi, S., Alsten, S. C. V., Zhang, Y., Kurç, T., Moffitt, R. A., Troester, M. A., et al. (2022) · Cancers · doi:10.3390/cancers14092148 · Cited by 62
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
Zhou, Y., Li, M., Zhou, K., Brown, J., Tsao, T., Cen, X., Husman, T., Bajpai, A., Dunn, Z. S., & Yang, L. (2022) · Cancers · doi:10.3390/cancers14092266 · Cited by 61
Substances of Natural Origin in Medicine: Plants vs. Cancer
Gielecińska, A., Kciuk, M., Mujwar, S., Çeli̇k, İ., Kołat, D., Kałuzińska‐Kołat, Ż., & Kontek, R. (2023) · Cells · doi:10.3390/cells12070986 · Cited by 64
ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade
Liu, X., Cen, X., Wu, R., Chen, Z., Xie, Y., Wang, F., Shan, B., Zeng, L., Zhou, J., Xie, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39920-5 · Cited by 60
Multiple cancer cell types release LIF and Gal3 to hijack neural signals
Xu, Q., Cao, Y., Kong, F., Liu, J., Chen, X., Zhao, Y., Lai, C., Zhou, X., Hu, H., Fu, W., et al. (2024) · Cell Research · doi:10.1038/s41422-024-00946-z · Cited by 61
Tumor antigen‐specific CD4 + T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies
Protti, M. P., Monte, L. B. D., & Lullo, G. D. (2014) · Tissue Antigens · doi:10.1111/tan.12329 · Cited by 60
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
Michaud, H., Eliaou, J., Lafont, V., Bonnefoy, N., & Gros, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955684 · Cited by 63
Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation
White, M. J. V., Roife, D., & Gomer, R. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500365 · Cited by 60
Molecular mechanisms of curcumins suppressing effects on tumorigenesis, angiogenesis and metastasis, focusing on NF-κB pathway
Panahi, Y., Darvishi, B., Ghanei, M., Jowzi, N., Beiraghdar, F., & Varnamkhasti, B. S. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.12.004 · Cited by 63
The multifaceted role of autophagy in tumor evasion from immune surveillance
Janji, B., Viry, E., Moussay, E., Paggetti, J., Arakelian, T., Mgrditchian, T., Messai, Y., Noman, M. Z., Moer, K. V., Hasmim, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7540 · Cited by 61
Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Ye, Z., Dong, H., Li, Y., Ma, T., Huang, H., Leong, H. S., Eckel‐Passow, J. E., Kocher, J., Liang, H., & Wang, L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3008 · Cited by 64
5-Hydroxytryptamine1a receptors on tumour cells induce immune evasion in lung adenocarcinoma patients with depression via autophagy/pSTAT3
Liu, Y., Zhang, H., Wang, Z., Pin, W., & Gong, W. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.017 · Cited by 64
Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients
Hiraoka, N., Ino, Y., Hori, S., Yamazaki–Itoh, R., Naito, C., Shimasaki, M., Esaki, M., Nara, S., Kishi, Y., Shimada, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14514 · Cited by 59
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Segura‐Collar, B., Hiller-Vallina, S., de Dios, O., Caamaño-Moreno, M., Mondéjar-Ruescas, L., Sepúlveda-Sánchez, J. M., & Gargini, R. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01569-y · Cited by 63
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
Zhou, Z., Wang, J., Wang, J., Yang, S., Wang, R., Zhang, G., Li, Z., Shi, R., Wang, Z., & Lu, Q. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02047-2 · Cited by 66
Expansion of tumor-reactive CD8 + T cell clonotypes occurs in the spleen in response to immune checkpoint blockade
Morgan, D. M., Horton, B. L., Bhandarkar, V., Van, R., Dinter, T., Zagorulya, M., Love, J. C., & Spranger, S. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi3487 · Cited by 62
Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers
Moon, H., Oh, K., Lee, J., Lee, M., Kim, J.-Y., Yoo, T.-K. R., Seo, M. W., Park, A. K., Ryu, H. S., Jung, E., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3585-y · Cited by 59
The transcription factor BACH2 promotes tumor immunosuppression
Roychoudhuri, R., Eil, R. L., Clever, D. C., Klebanoff, C. A., Sukumar, M., Grant, F. M., Yu, Z., Mehta, G. U., Liu, H., Jin, P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82884 · Cited by 59
Applying nanomedicine in maladaptive inflammation and angiogenesis
Alaarg, A., Pérez‐Medina, C., Metselaar, J. M., Nahrendorf, M., Fayad, Z. A., Storm, G., & Mulder, W. J. M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.009 · Cited by 60
Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome
Guerra, D. A. P., Paiva, A. E., Sena, I. F. G., de Azevedo, P. O., da Silva, W. N., Mintz, A., & Birbrair, A. (2018) · Angiogenesis · doi:10.1007/s10456-018-9621-x · Cited by 59
Diagnosis of immunomarkers in vivo via multiplexed surface enhanced Raman spectroscopy with gold nanostars
Ou, Y., Webb, J. A., O'Brien, C. M., Pence, I. J., Lin, E. C., Paul, E. P., Cole, D., Ou, B. S., Lapierre-Landry, M., DeLapp, R. C., et al. (2018) · Nanoscale · doi:10.1039/c8nr01478g · Cited by 59
E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions
Hosseini, S. M., Okoye, I., Chaleshtari, M. G., Hazhirkarzar, B., Mohamadnejad, J., Azizi, G., Hojjat‐Farsangi, M., Mohammadi, H., Shotorbani, S. S., & Jadidi‐Niaragh, F. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.08.020 · Cited by 59
Cancer Immunosurveillance by T Cells
Rao, S., Gharib, K., & Han, A. S. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.08.001 · Cited by 60
A Combination of Cowpea Mosaic Virus and Immune Checkpoint Therapy Synergistically Improves Therapeutic Efficacy in Three Tumor Models
Wang, C., & Steinmetz, N. F. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202002299 · Cited by 57

Authors: Gajewski, T. F., Schreiber, H., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Gajewski, Thomas F
ORCID: Schreiber, Hans
Fu, Yang-Xin
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-09-18
Volume: 14
Issue: 10
Pages: 1014-1022
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2703
PMC: PMC4118725
OpenAlex: W2042699075
Cited by: 4,148
References: 149
Citations by year: 2026: 187 · 2025: 310 · 2024: 432 · 2023: 486 · 2022: 443 · 2021: 522 · 2020: 372 · 2019: 315 · 2018: 290 · 2017: 290 · 2016: 240 · 2015: 162 · 2014: 82 · 2013: 1
FWCI: 17.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA161005, R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: tumor microenvironment, tumor immune evasion, innate immunity, adaptive immunity, CD8+ T cells, immune exclusion, type I interferon signature, chemokine profile, immune checkpoint blockade, cancer immunotherapy
MeSH terms: Animals, Dendritic Cells, Humans, Immunity, Innate, Lymphocyte Activation, Neoplasms, T-Lymphocyte Subsets, Stromal Cells, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Innate and adaptive immune cells in the tumor microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks